Absci Corporation (ABSI) NASDAQ
4.95
+0.32(+6.91%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.95
+0.32(+6.91%)
Currency In USD
| Previous Close | 4.63 |
| Open | 4.68 |
| Day High | 4.99 |
| Day Low | 4.66 |
| 52-Week High | 6.72 |
| 52-Week Low | 2.24 |
| Volume | 3.41M |
| Average Volume | 5.16M |
| Market Cap | 771.73M |
| PE | -6.04 |
| EPS | -0.82 |
| Moving Average 50 Days | 3.82 |
| Moving Average 200 Days | 3.33 |
| Change | 0.32 |
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci’s Scientific Advisory Board VANC
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report b
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 16, 2025 1:00 PM GMT
VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating